Evaluating Choice of Biologics for Isolated Small-Bowel Crohn's Disease
- PMID: 41338240
- DOI: 10.1093/ibd/izaf294
Evaluating Choice of Biologics for Isolated Small-Bowel Crohn's Disease
Keywords: Crohn's disease; small bowel; vedolizumab.
Plain language summary
In this study we evaluated the effectiveness of vedolizumab (anti-integrin) vs ustekinumab/risankizumab (anti-interleukin) therapy for isolated small-bowel Crohn’s disease using a real-world, multicenter national database. We found that anti-interleukin therapy was more effective for inducing steroid-free remission and reducing hospitalizations.
LinkOut - more resources
Full Text Sources
